Evaluation of the Efficacy of the NK1 Antagonist GR205171 in Posttraumatic Stress Disorder.

Trial Profile

Evaluation of the Efficacy of the NK1 Antagonist GR205171 in Posttraumatic Stress Disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2015

At a glance

  • Drugs Vofopitant (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Dec 2010 Results have been published in European Neuropsychopharmacology.
    • 01 Sep 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top